Literature DB >> 8971763

Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death.

E Morishita1, S Masuda, M Nagao, Y Yasuda, R Sasaki.   

Abstract

Recently, erythropoietin has been shown to be produced by astrocytes and its production is hypoxia-inducible. In the present study, we demonstrated, using a reverse transcription-polymerase chain reaction assay and immunostaining of the cells, that the erythropoietin receptor was expressed in cultured hippocampal and cerebral cortical neurons of day 19 rat embryo. Erythropoietin protected the cultured neurons from glutamate neurotoxicity. Neurons cultured for seven to 10 days were exposed to glutamate for 15 min and after culture for a further 24 h in the absence of glutamate the neuron survival was assayed. Significant protection was observed with erythropoietin from 3 pM (c. 100 pg/ml) in a dose-dependent manner. The protection was completely reversed by co-application of a soluble erythropoietin receptor, an extracellular domain capable of binding with erythropoietin. For exhibition of the neuroprotective effect, exposure of neurons to erythropoietin approximately 8 h prior to exposure to glutamate was required. Experiments with the inhibitors indicated that RNA and protein syntheses were necessary for the protection. However, exposure to erythropoietin for a short period (5 min or less) was sufficient to elicit the protective effect. The protective effect of erythropoietin was blocked by the simultaneous addition of EGTA. These findings and the previous finding that erythropoietin induces a rapid and transient increase in intracellular Ca2+ concentration in neuronal cells suggest that erythropoietin plays a neuroprotective role in brain injury caused by hypoxia or ischemia and that erythropoietin-induced Ca2+ influx from outside of the cells is a critical initial event yielding an enhanced resistance of the neurons to glutamate toxicity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8971763     DOI: 10.1016/s0306-4522(96)00306-5

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  136 in total

Review 1.  Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy.

Authors:  Cristina Hernández; Rafael Simó
Journal:  Endocrine       Date:  2011-12-14       Impact factor: 3.633

2.  GATA-binding protein 4 (GATA-4) and T-cell acute leukemia 1 (TAL1) regulate myogenic differentiation and erythropoietin response via cross-talk with Sirtuin1 (Sirt1).

Authors:  Li Wang; Yi Jia; Heather Rogers; Yun-Ping Wu; Suming Huang; Constance Tom Noguchi
Journal:  J Biol Chem       Date:  2012-07-07       Impact factor: 5.157

3.  Erythropoietin: still on the neuroprotection road.

Authors:  Nelvys Subirós; Diana García Del Barco; Rosa M Coro-Antich
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

4.  Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity.

Authors:  Zhao Zhong Chong; Faqi Li; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2005-12       Impact factor: 1.990

5.  Intersecting guidelines: administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer.

Authors:  Charles L Bennett; Pamela S Becker; Eric H Kraut; Athena T Samaras; Dennis P West
Journal:  Semin Dial       Date:  2008-12-05       Impact factor: 3.455

6.  Erythropoietin concentration in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.

Authors:  P Janik; H Kwiecinski; B Sokolowska; I Niebroj-Dobosz
Journal:  J Neural Transm (Vienna)       Date:  2009-12-12       Impact factor: 3.575

Review 7.  Role of signal transducer and activator of transcription 3 in neuronal survival and regeneration.

Authors:  Suzan Dziennis; Nabil J Alkayed
Journal:  Rev Neurosci       Date:  2008       Impact factor: 4.353

8.  A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial.

Authors:  Béatrice Weber; Rémy Largillier; Isabelle Ray-Coquard; Gabriel Yazbek; Jérôme Meunier; Jérôme Alexandre; Jérôme Dauba; Dominique Spaeth; Rémy Delva; Florence Joly; Eric Pujade-Lauraine; Laure Copel
Journal:  Support Care Cancer       Date:  2013-02-19       Impact factor: 3.603

9.  Promotion of neurite outgrowth and protective effect of erythropoietin on the retinal neurons of rats.

Authors:  Yisheng Zhong; Huiping Yao; Lianfu Deng; Yu Cheng; Xiaoqing Zhou
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-09-09       Impact factor: 3.117

Review 10.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.